(19)
(11) EP 2 136 836 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.04.2017 Bulletin 2017/15

(45) Mention of the grant of the patent:
04.01.2017 Bulletin 2017/01

(21) Application number: 08745178.7

(22) Date of filing: 04.04.2008
(51) International Patent Classification (IPC): 
A61K 39/04(2006.01)
A61P 31/06(2006.01)
C07K 14/285(2006.01)
A61K 39/00(2006.01)
 C07K 14/35(2006.01)
G01N 33/569(2006.01)
G01N 33/68(2006.01)
(86) International application number:
PCT/US2008/059500
(87) International publication number:
WO 2008/124647 (16.10.2008 Gazette 2008/42)

(54)

IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF

IMMUNOGENE ZUSAMMENSETZUNGEN MIT MYCOBACTERIUM TUBERCULOSIS-POLYPEPTIDEN UND FUSIONEN DARAUS

COMPOSITIONS IMMUNOGÈNES COMPORTANT DES POLYPEPTIDES DE<I>MYCOBACTERIUM</I><I>TUBERCULOSIS</I>ET DES FUSIONS DE CEUX-CI

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 04.04.2007 US 910169 P

(43) Date of publication of application:
30.12.2009 Bulletin 2009/53

(60) Divisional application:
16206308.5

(73) Proprietor: Infectious Disease Research Institute
Seattle, Washington 98102 (US)

(72) Inventors:
  • REED, Steven, G.
    Bellevue, Washington 98005 (US)
  • COLER, Rhea, N.
    Seattle, WA 98199 (US)
  • IRETON, Gregory, C.
    Seattle, WA 98115 (US)
  • Sylvie Bertholet
    53100 Siena (IT)

(74) Representative: Grünecker Patent- und Rechtsanwälte PartG mbB 
Leopoldstraße 4
80802 München
80802 München (DE)


(56) References cited: : 
EP-A- 1 484 405
WO-A-01/98460
WO-A-2004/006952
WO-A-2006/136162
 WO-A-01/24820
WO-A-99/51748
WO-A-2006/026404
   
  • TSENOVA L ET AL: "Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, vol. 74, no. 4, 1 January 2006 (2006-01-01), pages 2392-2401, XP002399918 ISSN: 0019-9567
  • CHAKHAIYAR P ET AL: "Regions of high antigenicity within the hypothetical PPE major polymorphic tandem repeat open-reading frame, Rv2608, show a differential humoral response and a low T cell response in various categories of patients with tuberculosis" JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, vol. 190, no. 7, 1 October 2004 (2004-10-01), pages 1237-1244, XP003018498 ISSN: 0022-1899
  • COLE S T ET AL: "DECIPHERING THE BIOLOGY OF MYCOBACTERIUM TUBERCULOSIS FROM THE COMPLETE GENOME SEQUENCE" NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 393, 11 June 1998 (1998-06-11), pages 537-563, XP002938231 ISSN: 0028-0836
  • HOUGHTON RAYMOND L ET AL: "Use of multiepitope polyproteins in serodiagnosis of active tuberculosis" CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, vol. 9, no. 4, July 2002 (2002-07), pages 883-891, XP002511611 ISSN: 1071-412X
  • ABEBE F ET AL: "Progress in serodiagnosis of Mycobacterium tuberculosis infection" SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 66, no. 2-3, August 2007 (2007-08), pages 176-191, XP002511612 ISSN: 0300-9475
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).